Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Raises $26M from Biogen and Genentech, Appoints Two Executives

Premium

NEW HAVEN, Conn.--Cura-Gen has exercised its right under existing collaborative agreements with Biogen and Genentech to borrow a total of $26 million. Simultaneously, CuraGen converted these loans into approximately 1.6 million shares of CuraGen stock at $16 a share. These transactions increased Biogen's equity position in CuraGen by $10 million and Genentech's position by $16 million, combining to provide CuraGen with an additional $26 million in cash. This follows a $15 million private placement investment in CuraGen by Pequot Capital Management last month.

In other news, the company has appointed Christopher McLeod as executive vice-president and Peter Lomedico as vice-president of discovery research. Reporting to chairman and CEO Jonathan Rothberg, McLeod will oversee bioinformatics and strategic business development and participate in the execution of overall corporate operations. Lomedico will work closely with the company's business development team, overseeing all external collaborations. Previously, he was vice-president of human genetics at Genome Therapeutics.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.